✦ LIBER ✦

1223 A model of synergistic antitumour activity of sorafenib, a multikinase inhibitor of Raf, VEGF and PDGF receptors, with anti-EGFR inhibitors (cetuximab and erlotinib) in a panel of colorectal and lung cancer cell lines

✍ Scribed by E. Martinelli; T. Troiani; F. Morgillo; L. Vecchione; M. Orditura; F. De Vita; G. Rodolico; L. Berrino; F. Ciardiello

Book ID: 119600196
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)70435-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Synergistic anti-proliferative and pro-a

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

✍ Tina Cascone; Maria Pia Morelli; Floriana Morgillo; Woo-Young Kim; Gabriella Rod 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 1 views

## Abstract The proteasome plays a pivotal role in the turnover of regulatory transduction proteins induced by activated cell membrane growth factor receptors. The epidermal growth factor receptor (EGFR) pathway is crucial in the development and progression of human epithelial cancers. Proteasome i

Synergistic anti-proliferative and pro-a

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

✍ Tina Cascone; Maria Pia Morelli; Floriana Morgillo; Woo-Young Kim; Gabriella Rod 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB 👁 1 views